Sanara MedTech Inc. (SMTI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed strong financial performance with 22% revenue growth and a significant increase in operating income and net income. The company is focusing on profitable growth and has reduced cash investment in non-core areas. Despite some uncertainties in OsStic's regulatory path and unclear forward guidance, the positive financial results and strategic focus on core areas suggest a positive stock price reaction.
Key Financial Performance
Net Revenue $26.3 million, representing growth of 22% year-over-year. The growth was driven almost exclusively by sales of soft tissue repair products, which increased 24% year-over-year to $23.4 million, led by strong sales of CellerateRX Surgical and BIASURGE.
Gross Profit $24.5 million, an increase of $4.8 million or 24% year-over-year. Gross margin increased approximately 200 basis points to 93% of net revenue, driven primarily by increased sales of soft tissue repair products.
Operating Income $2.9 million, an increase of $2.2 million or 278% year-over-year. This was driven by higher net revenue and improved operating leverage.
Net Income from Continuing Operations $800,000 or $0.09 per diluted share, compared to a net loss of $200,000 or $0.02 per diluted share last year. This improvement was attributed to increased revenue and profitability.
Adjusted EBITDA $4.9 million, an increase of $2.3 million year-over-year, driven by higher net revenue and improved operating leverage.
Net Cash from Operating Activities $2.2 million generated in the third quarter, reflecting strong operational performance.
Operating Expenses $21.5 million, an increase of $2.6 million or 14% year-over-year. This was driven by a $2.5 million or 14% increase in selling, general and administrative expenses and a $200,000 or 31% increase in research and development expenses.
Cash and Long-Term Debt $14.9 million of cash and $45.1 million of long-term debt as of September 30, 2025, compared to $15.9 million of cash and $30.7 million of long-term debt as of December 31, 2024. The increase in debt was attributed to higher interest expense and fees related to the CRG term loan.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CellerateRX and BIASURGE: Key products that have shown utility in clinical practice, improving patient outcomes and reducing healthcare costs. Sales of these products increased 24% year-over-year to $23.4 million.
OsStic: An innovative product for periarticular fractures, granted Breakthrough Device designation by the FDA. Anticipated U.S. commercial launch in Q1 2027.
Healthcare facility expansion: Products sold into more than 1,400 healthcare facilities in the trailing 12 months, up from 1,200 in the prior year. Products are approved in over 4,000 facilities, indicating significant growth potential.
Independent distributor network: Expanded from 300 to over 400 contracted distributors in the last 12 months, enhancing market reach.
Tissue Health Plus (THP) discontinuation: Ceased operations of THP to focus on core surgical business. Expected cash investment of $5.5M-$6.5M in H2 2025, with no material cash spend after 2025.
Revenue and profitability: Net revenue for Q3 2025 was $26.3M, a 22% year-over-year growth. Gross margin improved to 93%, and adjusted EBITDA increased by $2.3M to $4.9M.
Focus on surgical business: Strategic realignment to enhance operational efficiency and capitalize on strengths in the surgical market.
Clinical evidence and publications: Two studies published demonstrating the efficacy of CellerateRX in challenging surgical procedures, enhancing product credibility.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Ceasing Operations of Tissue Health Plus (THP): The decision to cease operations of THP was driven by the inability to find a strategic partner or monetize the asset. Continuing THP would have required significant investment over multiple years, which could have strained resources and impacted operational efficiency.
Cash Investment in THP Wind-Down: The company anticipates a total cash investment of $5.5 million to $6.5 million in the second half of 2025 for winding down THP operations. This represents a financial burden in the short term, though no material cash spend is expected after 2025.
Increased Operating Expenses: Operating expenses increased by $2.6 million (14%) in the third quarter, driven by higher compensation, contract services, and sales and marketing expenses. This could pressure profitability if revenue growth does not keep pace.
Debt Levels: The company reported $45.1 million in long-term debt as of September 30, 2025, up from $30.7 million at the end of 2024. This increase in debt could pose financial risks, especially if interest rates rise or cash flow weakens.
Low Penetration in Existing Healthcare Facilities: Despite being approved in over 4,000 facilities, the company has low penetration in the 1,400 facilities it currently serves. This represents both a challenge and an opportunity for growth.
Regulatory and Development Risks for OsStic: The OsStic product, while promising, is not yet cleared for sale in the U.S. and is subject to regulatory and development milestones. Delays or failures in achieving these milestones could impact future growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects net revenue in the fourth quarter of 2025 to increase in the high single digits to low teens year-over-year, excluding a $1.8 million headwind from exceptional performance in Q4 2024.
Cash Utilization: The total cash investment related to THP is expected to range from $5.5 million to $6.5 million in the second half of 2025, with no material cash spend anticipated after 2025.
Product Launch: The U.S. commercial launch of OsStic is anticipated in the first quarter of 2027.
Market Expansion: The company plans to continue expanding its base of healthcare facility customers and increasing penetration within existing facilities, targeting practitioners both within and outside traditional specialties of spine and orthopedics.
Profitability: The company aims to improve profitability on a continuing operations basis for the full year 2025.
Operational Efficiency: The company is focused on enhancing operational efficiency and investing prudently in its Surgical business after discontinuing THP operations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you spend more time on your initiatives in driving further penetration within existing facilities? How do your conversations go with new physicians? What are people excited about? What do they have more questions about?
A:The company has expanded into new specialties through efforts at the street level with the sales force, both on the W-2 side and distributor side. The R&D and clinical teams have worked on scientific, clinical, and economic evidence to support the value of their products. They aim to replicate their successful formula and get creative as they move into 2026 and beyond.
Q:When thinking about operating profitability, are there areas outside of THP where we should expect cash savings? Or should we begin to expect leverage on sales and marketing going forward?
A:The company has kept its headcount and sales flat with 40 reps and 400 distributors, showing operating leverage on the EBITDA line. They are focused on sustainable and profitable growth, investing in their product portfolio and IP. They see leverage in their sales channel and will no longer spend cash flow in the THP segment.
Q:Based on your outlook for the next quarter, is growth going to be high single digits, low teens? How do you think about the cadence and internal thresholds? What is the long-term operating margin target?
A:The company grew 49% in Q4 2024, or 38% excluding a $1.8 million adjustment. They remain confident in their ability to perform at a high level in the new year, given their opportunities, approved facilities, and distributor partnerships. They do not provide forward-looking guidance but feel good about their performance and margin expansion potential.
Q:A strategic partner was expected to be required to bring THP to the market. Why was a strategic partner not considered as an integral part before the costs were incurred?
A:The company pursued a strategic partner starting in March 2024, hoping the developed software and beta sites would encourage activity. Unfortunately, this did not materialize, leading to a decision to discontinue THP and reallocate resources to the surgical space.
Q:Now that the THP is going to be discontinued, could you comment on the trend of total operating expenses? Should we project to see a meaningful decrease in operating expenses?
A:The company does not provide forward-looking guidance but has supplemental disclosures on their website that examine the Surgical business as a stand-alone business historically. This information can be used to model trends.
Q:Review of Unclear Management Responses
A:Management avoided giving direct answers to forward-looking questions, such as specific growth rates, long-term operating margin targets, and trends in operating expenses. They emphasized historical performance and confidence in their strategy but did not provide detailed projections or benchmarks.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BMI
Directors
Foot Ankle
MedTech
THP cash
THP progress
THP segment
adviser
alternative
announcement yesterday
background
basis respect
case
cash investment
cash spend
cash term
context
cost
decision THP
effectiveness
facility approval
healing
health care
healthcare facility
investment THP
lobectomy
milestone
option
partnering distributor
product healthcare
publication
researcher
sale manager
section
segment month
series
spend THP
stage
use CellerateRX
year
yesterday Tissue
SMTI Transcript
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call reveals strong financial performance with a 19% revenue increase and improved margins, despite increased operating expenses. The Q&A section highlights robust product support and strategic expansion initiatives. Although guidance remains unchanged, the company's strategic focus on R&D and competitive positioning is promising. The lack of negative sentiment from analysts and no unclear management responses further support a positive outlook. However, increased expenses and debt levels pose some risks, tempering the sentiment from strong positive to positive.
Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary highlights a strong financial performance with a 15% YoY increase in Q4 net revenue and a 20% growth for the full year 2025. This is attributed to successful product launches and market expansion. Despite the absence of discussions on operational updates, risks, or shareholder returns, the positive revenue performance suggests a favorable market reaction. The lack of additional insights from the Q&A section does not detract from the strong financial indicators. Therefore, a positive sentiment is justified.
Sanara MedTech Inc. (SMTI) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call showed strong financial performance with 22% revenue growth and a significant increase in operating income and net income. The company is focusing on profitable growth and has reduced cash investment in non-core areas. Despite some uncertainties in OsStic's regulatory path and unclear forward guidance, the positive financial results and strategic focus on core areas suggest a positive stock price reaction.
Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights strong financial performance with 28% YoY revenue growth, improved gross margins, and a significant increase in adjusted EBITDA. Despite a consolidated net loss, the surgical segment shows profitability and operational efficiency. The Q&A reveals strategic investments and growth in key products like Cellerate and BIASURGE. However, management's lack of clarity on future OpEx and R&D timelines is a slight concern. Overall, the positive financial metrics and growth prospects outweigh uncertainties, suggesting a positive stock price reaction in the short term.
SMTI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
